Children's National Hospital is the first pediatric hospital to administer a commercial dose of Elevidys (delandistrogene moxeparvovec-rokl), the first gene therapy for the treatment of pediatric patients with Duchenne muscular dystrophy (DMD). On the day before his 6 th birthday, Hiram, 5, was the first patient ever with DMD to receive the drug after the U.S. Food and Drug Administration (FDA) approved its use last month . "The approval of Elevidys opens a new door for young patients with DMD and their families," says Sarah Wright, D.

https://www.miragenews.com/first-commercial-dose-of-fda-approved-duchenne-1058883/

#miragenews